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Visual Abstract
The cholesterol-lowering drug lovastatin corrects neurological phenotypes in animal models of fragile X syndrome
(FX), a commonly identified genetic cause of autism and intellectual disability (ID). The therapeutic efficacy of
lovastatin is being tested in clinical trials for FX; however, the structurally similar drug simvastatin has been
proposed as an alternative due to an increased potency and brain penetrance. Here, we perform a side-by-side
comparison of the effects of lovastatin and simvastatin treatment on two core phenotypes in Fmr1-/y mice versus
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WT littermates: excessive hippocampal protein synthesis and susceptibility to audiogenic seizures (AGSs). We
find that simvastatin does not correct excessive hippocampal protein synthesis in the Fmr1-/y hippocampus at any
dose tested. In fact, simvastatin significantly increases protein synthesis in both Fmr1-/y and WT. Moreover,
injection of simvastatin does not reduce AGS in the Fmr1-/y mouse, while lovastatin significantly reduces AGS
incidence and severity versus vehicle-treated animals. These results show that unlike lovastatin, simvastatin does
not correct core phenotypes in the Fmr1-/y mouse model.
Key words: ERK; FMR1; fragile X; lovastatin
Introduction
Fragile X syndrome (FX) is a monogenic neurodevelop-
mental disorder characterized by severe intellectual dis-
ability (ID), autism, hypersensitivity to sensory stimulation
and epilepsy (Lozano et al., 2014). FX occurs in 1:4000
males and 1:8000 females, making it one of the most
commonly identified genetic causes of autism and ID
(Hagerman et al., 2009; Lozano et al., 2014). The FMR1
gene mutated in FX encodes fragile X mental retardation
protein (FMRP), which represses mRNA translation in
neurons (Ashley et al., 1993; Darnell et al., 2011). Studies
of the Fmr1-/y mouse model of FX reveal that excessive
cerebral protein synthesis is a major consequence of
Fmr1 deletion (Qin et al., 2005; Dölen et al., 2007; Berry-
Kravis et al., 2017; Stoppel et al., 2017b), which can be
normalized through antagonism of metabotropic gluta-
mate receptor 5 (mGlu5) or the downstream extracellular
regulated kinase 1/2 (ERK1/2) MAP kinase and mamma-
lian target of rapamycin (mTOR)-p70 S6 kinase (p70S6K)
signaling pathways (Dölen et al., 2007; Osterweil et al.,
2010; Sharma et al., 2010; Michalon et al., 2012; Wang
et al., 2012). These strategies correct multiple neurologic
phenotypes in the Fmr1-/y mouse, including an enhanced
susceptibility to audiogenic seizures (AGSs; Bear et al.,
2004; Dölen et al., 2007; Osterweil et al., 2010; Stoppel
et al., 2017a). The current challenge is to successfully
transition these therapeutic approaches to the clinic.
Previous work shows that the statin drug lovastatin,
currently used for the treatment of high cholesterol in
adults and children, resolves neuropathology in the
Fmr1-/y mouse model (Osterweil et al., 2013). Lovastatin
normalizes protein synthesis by reducing the farnesylation
and subsequent activation of the GTPase Ras, which lies
upstream of the ERK1/2 signaling pathway (Schafer et al.,
1989; Mendola and Backer, 1990). By this mechanism,
lovastatin has also been shown to successfully correct
electrophysiological and behavioral phenotypes in the
mouse model of neurofibromatosis type 1 (NF1), a neu-
rodevelopmental disorder of excess Ras (Li et al., 2005).
In contrast to ERK1/2, the mTOR-p70S6K pathway acti-
vated by the GTPase Rheb is not altered by lovastatin
suggesting the impact on farnesylation does not extend to
all targets (Osterweil et al., 2013).
In the Fmr1-/y mouse, the reduction of Ras-ERK1/2 by
lovastatin ameliorates hippocampal epileptogenesis and
neocortical hyperexcitability and significantly reduces the
incidence of AGS (Osterweil et al., 2013). The AGS phe-
notype is one of the most robust behavioral phenotypes
seen in the Fmr1-/y mouse, and it models the epilepsy
observed in FX patients (Musumeci et al., 2000; Berry-
Kravis, 2002). Several previous studies have used AGS as
a benchmark for determining the efficacy of potential
treatment strategies, consistently finding a positive corre-
lation between treatment efficacy at reducing seizure in-
cidence and correction of other pathologies (Yan et al.,
2005; Dölen et al., 2007; Osterweil et al., 2010, 2013;
Busquets-Garcia et al., 2013; King and Jope, 2013).
Based on the positive outcome with lovastatin in Fmr1-/y
animal models, two open-label clinical trials tested the
viability of lovastatin for the treatment of FX (Çaku et al.,
2014; Pellerin et al., 2016). Both studies revealed a sig-
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Significance Statement
The statin drug lovastatin is in clinical trials for the treatment of fragile X syndrome (FX), and the structurally similar
drug simvastatin has been proposed as a viable alternative. This study compares the efficacy of these drugs for
ameliorating two major phenotypes in the FX mouse model and shows that although lovastatin is effective in
correcting excessive protein synthesis and audiogenic seizures (AGSs), simvastatin fails to correct either
phenotype. These results suggest caution should be used when assuming simvastatin is a suitable substitute for
lovastatin with respect to the treatment of FX or other neurodevelopmental disorders.
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nificant improvement with lovastatin treatment, and a
double-blind placebo-controlled trial is ongoing (Berry-
Kravis et al., 2017).
Interestingly, the availability of lovastatin is not wide-
spread in Europe and is not licensed for use in the United
Kingdom. Instead, the drug simvastatin has been pro-
posed as an alternative therapeutic. Simvastatin is a
structurally similar derivative of lovastatin that is twice as
potent, with a daily dose of only 10 mg reducing choles-
terol by 25–30% compared to 20 mg of lovastatin (Jones
et al., 1998; Schaefer et al., 2004; Neuvonen et al., 2008).
Simvastatin is also more brain penetrant than lovastatin,
suggesting it may be a better option for neurologic indi-
cations (Tsuji et al., 1993). However, simvastatin has not
been investigated in the Fmr1-/y model, and the impact on
Ras-ERK1/2 signaling in the brain is not well established.
This information is critical, as clinical trials in NF1 have
recently shown that lovastatin has a beneficial impact on
cognitive function whereas simvastatin does not (Krab
et al., 2008; Alabama-Birmingham and NCI, 2009, 2010;
van der Vaart et al., 2013; Bearden et al., 2016; Payne
et al., 2016).
In this study, we performed a side-by-side comparison
of lovastatin and simvastatin to answer the simple but
important question of whether there is a similar rescue of
pathology in the Fmr1-/y mouse. We focused on two core
phenotypes in the Fmr1-/y model: excessive protein syn-
thesis and enhanced susceptibility to AGS. Importantly,
our results clearly show that lovastatin, but not simvasta-
tin, is effective in reducing ERK1/2 activity and normaliz-
ing protein synthesis in the Fmr1-/y hippocampus. This
suggests that simvastatin acts via a different mechanism
from lovastatin with respect to ERK1/2-driven protein
synthesis in the brain. To examine whether there was a
similar impact on pathology, we performed a thorough
AGS analysis using multiple doses of simvastatin. The
results of these experiments show that simvastatin does
not reduce the incidence or severity of AGS in the Fmr1-/y
mouse under conditions where lovastatin is significantly
effective. Together, this evidence suggests simvastatin
may not be a suitable replacement for lovastatin with
respect to the treatment of FX.
Materials and Methods
Mice
All mice tested were male and were naive to drug and
behavioral testing before experimentation. Mice were group
housedwith unrestricted food andwater access and a 12/12
h light/dark cycle. Room temperature was maintained at 21
 2°C. All animal procedures were performed in accordance
with the University of Edinburgh animal care committee’s
regulations and the United Kingdom Animals Act. Fmr1-/y
mice (The Jackson Laboratory 003025, RRID:IMSR_JAX:
003025) were maintained on either a C57BL/6J (Charles
River) or a mixed C57BL/6J x FVB background (C57BL/6J
backcrossed to FVB by two generations).
Metabolic labeling
Hippocampal slices were prepared from male littermate
wild-type (WT) and Fmr1-/y (KO) C57BL/6J mice [postnatal
day (P)25–P32], in an interleaved fashion, with the exper-
imenter blind to genotype. Mice were anaesthetized with
isoflurane, and the hippocampus was rapidly dissected in
ice-cold ACSF (124 mM NaCl, 3 mM KCl, 1.25 mM
NaH2PO4, 26 mM NaHCO3, 10 mM dextrose, 1 mM
MgCl2, and 2 mM CaCl2, saturated with 95% O2 and 5%
CO2). Slices (500 m thick) were prepared using a Stoelt-
ing Tissue Slicer and transferred into 32.5°C ACSF (satu-
rated with 95% O2 and 5% CO2) within 5 min. Slices were
incubated in 32.5°C ACSF for 4 h to allow for recovery of
protein synthesis then transferred to ACSF containing 25
M Actinomycin D (Tocris) plus either vehicle (0.05%
DMSO in ddH2O), 50 M lovastatin active form (CAS
75225-50-2; Calbiochem Merck Millipore), or 0.1–5 M
simvastatin active form (CAS 101314-97-0; Cayman
Chemical) for 30 min. To measure new protein synthesis,
slices were then transferred to fresh ACSF with 10 Ci/ml
35S-Met/Cys (PerkinElmer) containing vehicle (veh) or
drug for another 30 min.
After labeling, slices were homogenized in ice-cold buf-
fer (10 mM HEPES, pH 7.4, 2 mM EDTA, 2 mM EGTA, 1%
Triton X-100, protease inhibitors, and phosphatase inhib-
itors) and incubated in trichloroacetic acid (TCA; 10%
final) for 10 min on ice before being centrifuged at 16,000
rpm for 10 min. The pellet was washed in ice-cold ddH2O
and resuspended in 1 N NaOH until dissolved, and the pH
was readjusted to neutral using 0.33 N HCl. Triplicates of
each sample were subjected to scintillation counting and
protein concentration assay kit (Bio-Rad). Counts per
minute (CPM) were divided by protein concentration, and
this was normalized to the CPM from the ACSF used for
incubation. For display purposes, example slice homog-
enates were resolved on SDS-PAGE gels, transferred to
nitrocellulose and exposed to a phosphorimaging screen
(GE Healthcare). Phosphorimages were acquired using a
Typhoon scanner (GE Healthcare) and compared to total
protein staining of the same membrane.
Immunoblotting
Samples were loaded on SDS-PAGE gels, with all con-
ditions per littermate pair (i.e., WT veh, KO veh, WT drug,
KO drug) present on the same gel (Extended Data Fig.
2-1). Samples were coded such that the experimenter
was blinded to genotype and treatment. Gels were trans-
ferred to nitrocellulose and stained for total protein with
the Memcode Reversible staining kit (Pierce). To immu-
noblot for ERK1/2 and p70S6K in the same samples,
membranes were cut at 75, 50, and 37 kDa as shown in
Extended Data Figure 2-1. For membranes probed for
p-p70S6K, the portion of membrane above 75 kDa was
removed to eliminate the background p85S6K band rec-
ognized by this antibody. Each membrane was then
blocked with 5% BSA in TBS  0.1% Tween 20 and
incubated in primary antibody overnight at 4°C [Cell Sig-
naling Technology; phospho-ERK1/2 (Thr202/Tyr204)
1:2000 (#9106, RRID:AB_331768), ERK1/2 1:2000 (#9102,
RRID:AB_330744), phospho-p70S6K (Thr389) 1:1000
(#9234, RRID:AB_2269803), p70S6K 1:1000 (#2708,
RRID:AB_390722); Extended Data Fig. 2-1]. Membranes
were then washed, incubated with HRP-conjugated sec-
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ondary antibodies for 30 min (Cell Signaling; RRID:
AB_330924 and RRID:AB_2099233), and developed with
Clarity ECL (Bio-Rad). Densitometry was performed on
scanned blot films using Image Studio Lite software,
RRID: SCR_013715.
To compare phopho to total for each target in the same
lane, membranes developed for phospho [i.e., phosphor-
ylated (p-)ERK1/2] were stripped and reprobed for total
(i.e., ERK1/2). Phosphorylation of target proteins was cal-
culated as a ratio of phospho to total. To correct for
blot-to-blot variance, each signal was normalized to the
average signal of all lanes on the same blot. Values are
shown as a percentage of average WT vehicle for graph-
ical purposes. All membranes were analyzed with exper-
imenter blind to genotype and treatment.
AGSs
Test cohorts were counterbalanced for genotype and
treatment. Naive WT and Fmr1-/y male P18–P29 mice
bred on a mixed C57BL/6J x FVB background were
weighed and injected intraperitoneally with 3 mg/kg sim-
vastatin prodrug (CAS 79902-63-9), 50 mg/kg simvastatin
active form (CAS 101314-97-0), or 100 mg/kg lovastatin
active form (CAS 75225-50-2) or respective vehicle (3%,
20%, or 50% DMSO  10% Tween 80 in PBS). Animals
were then transferred to a quiet (60-dB ambient sound)
room for 1 h. For testing, animals were moved to a
transparent test chamber equipped with speakers and a
webcam and allowed to habituate for 1 min. Audiogenic
stimulation (recorded sampling of a modified personal
alarm) was passed through an amplifier and 2  50-W
speakers (KRK Rokit RP5 G3 Active Studio Monitor) to
produce a stimulus of 130 dB for 2 min. A decibel meter
was placed at a standard distance from the speakers to
ensure a stable emission of sound throughout each ses-
sion. Incidence and severity of seizures was scored and
video files for each session were saved. Latency was
measured as the number of seconds between onset of the
AGS stimulus and appearance of the first seizure. Stages
of AGS severity were assigned according to previous
work as follows: (1) wild running (WR; pronounced, undi-
rected running and thrashing), (2) clonic seizure (violent
spasms accompanied by loss of balance), or (3) tonic
seizure (loss of movement and postural rigidity in limbs
and tail). Any animal that reached tonic seizure was im-
mediately humanely killed. All injections, testing and scor-
ing was performed with the experimenter blind to
genotype and treatment.
Statistics
Statistical testing was performed using GraphPad
Prism 6 software, RRID: SCR_002798. For biochemistry
experiments, outliers2 SD from the mean were removed
and significance determined by repeated measures two-
way ANOVA and post hoc Sidak’s multiple comparisons
test. Significance for AGS incidence was determined us-
ing Fisher’s exact test. AGS severity score distributions
were tested for normality and found to be non-normal by
Shapiro–Wilk test. These score distributions were then
statistically compared using a Mann–Whitney U test for
analysis of ordinal datasets with non-normal distributions.
Significant differences in latency to first seizure were de-
termined using unpaired two-tailed Student’s t test. Re-
sults of all statistical analyses are reported in detail in the
statistical table (Table 1) and figure legends.
Results
Lovastatin, but not simvastatin, normalizes
excessive protein synthesis in the Fmr1-/y
hippocampus
Previous work shows that lovastatin normalizes exces-
sive protein synthesis in the Fmr1-/y hippocampus through
reduction of Ras-ERK1/2 activation, which corrects epi-
leptogenic phenotypes (Osterweil et al., 2013). To exam-
ine whether the same effect is seen with simvastatin, we
used a metabolic labeling assay in hippocampal slices
designed to assess protein synthesis in an intact prepa-
ration under physiologic conditions. Hippocampal slices
were prepared from juvenile WT and Fmr1-/y littermates,
blind to genotype, and allowed to recover in oxygenating
ACSF. Following this, slices were preincubated with Ac-
tinomycin D to block transcription, and new protein syn-
thesis was labeled through incorporation of 35S-labeled
methionine/cysteine mix (Fig. 1A).
Previous experiments tested a range of 10–50 M lo-
vastatin and showed that 50 M was effective in normal-
izing protein synthesis in the Fmr1-/y hippocampus
(Osterweil et al., 2013). To ensure that we could recapit-
ulate these results, we measured protein synthesis in WT
and Fmr1-/y slices 50 M lovastatin (Fig. 1B). As ex-
pected, our experiments revealed a significant correction
of excessive protein synthesis with lovastatin in the
Fmr1-/y mouse (WT veh  100  1.48%, WT lova 
100.06  4.87%, KO veh  117.97  4.27%, KO lova 
106.04  4.93%; WT vs KO veh p  0.0032, KO veh vs
lova p  0.0368; n  12). Next, we tested the efficacy of
simvastatin using the same assay system. As simvastatin
is twice as potent as lovastatin with respect to reducing
plasma LDL cholesterol levels in patients, we tested a
lower dose range of simvastatin in our metabolic labeling
assay (Tsuji et al., 1993; Jones et al., 1998; Schaefer et al.,
2004; Neuvonen et al., 2008). This concentration is con-
sistent with previous studies of simvastatin in cultured
neurons (Lim et al., 2006; Johnson-Anuna et al., 2007;
Mans et al., 2010). Interestingly, we find that simvastatin
treatment not only fails to reduce protein synthesis in the
Fmr1-/y hippocampus, it causes a significant increase in
both WT and Fmr1-/y slices at 5 M (WT vehicle  100 
2.70%, WT 5 M  153.5  6.32%, KO vehicle  111 
4.27%, KO 5 M  170.60  9.43%; WT veh vs 5 M p
 0.0001, KO veh vs 5 M p  0.0001; n  10; Fig. 1C).
This puzzling increase in protein synthesis led us to
wonder whether a reduced concentration of simvastatin
might be more appropriate. To test this, we exposed
slices to vehicle or simvastatin at concentrations of 0.1–
0.5 M. Surprisingly, we find that even at these lower
concentrations simvastatin causes a dose-dependent in-
crease in protein synthesis, worsening the Fmr1-/y pheno-
type (WT veh  100  2.21%, WT 0.1 M  106.99 
3.51%, WT 0.3 M  117.79  4.08%, WT 0.5 M 
124.13  4.23%, KO veh  115.61  3.48%, KO 0.1 M
New Research 4 of 12
May/June 2019, 6(3) e0097-19.2019 eNeuro.org
Table 1. Statistics table
Figure Data structure Statistical test Sample size Statistical data
Figure 1B, metabolic labelling of protein synthesis with 50 M lovastatin/vehicle
Normally distributed Two-way RM ANOVA N  12
per group
Genotype: p  0.0106
WT veh vs Fmr1
KO veh
Normally distributed Sidak’s post hoc N  12
per group
CI: –0.2916 to –0.06786,
p  0.0032
WT 50 M lovastatin vs
Fmr1 KO 50 M
lovastatin
Normally distributed Sidak’s post hoc N  12
per group
CI: –0.1716 to 0.05214,
p  0.3516
Fmr1 KO vehicle vs
Fmr1 KO 50 M
lovastatin
Normally distributed Sidak’s post hoc N  12
per group
CI: 0.007476 to 0.2312,
p  0.0368
Figure 1C, metabolic labelling of protein synthesis with 1–5 M simvastatin/vehicle






WT veh vs KO veh Normally distributed Sidak’s post hoc N  10
per group
CI: –0.3188 to 0.09835,
p  0.3451
WT veh vs KO veh Normally distributed Paired t test N  10
per group
CI: 0.008558 to 0.2119,
p  0.0366
WT veh vs WT 5 M
simvastatin
Normally distributed Sidak’s post hoc N  10
per group
CI: –0.7435 to –0.3263,
p  0.0001
Fmr1 KO veh vs
Fmr1 KO 5 M
simvastatin
Normally distributed Sidak’s post hoc N  10
per group
CI: –0.8045 to –0.3873,
p  0.0001
Figure 1D, metabolic labelling of protein synthesis with 0.1–0.5 M simvastatin/vehicle
Normally distributed Two-way RM ANOVA N  9
per group
Treatment: p  0.0001,
genotype:
p  0.0068
WT veh vs Fmr1 KO veh Normally distributed Sidak’s post hoc N  9
per group
CI: –0.2483 to –0.06400,
p  0.0005
WT veh vs WT 0.3 M
simvastatin
Normally distributed Sidak’s post hoc N  9
per group
CI: –0.2760 to –0.07980,
p  0.0002
WT veh vs WT 0.5 M
simvastatin
Normally distributed Sidak’s post hoc N  9
per group
CI: –0.3394 to –0.1432,
p  0.0001
Fmr1 KO veh vs
Fmr1 KO 0.3 M
simvastatin
Normally distributed Sidak’s post hoc N  9
per group
CI: –0.2334 to –0.03724,
p  0.0035
Fmr1 KO veh vs
Fmr1 KO 0.5 M
simvastatin
Normally distributed Sidak’s post hoc N  9
per group
CI: –0.3121 to –0.1159,
p  0.0001
WT 0.1 M simvastatin vs
Fmr1 KO 0.1 M
simvastatin
Normally distributed Sidak’s post hoc N  9
per group
CI: –0.1874 to –0.003152,
p  0.0406
WT 0.3 M simvastatin vs
Fmr1 KO 0.3 M
simvastatin
Normally distributed Sidak’s post hoc N  9
per group
CI: –0.2057 to –0.02143,
p  0.0115
WT 0.5 M simvastatin vs
Fmr1 KO 0.5 M
simvastatin
Normally distributed Sidak’s post hoc N  9
per group
CI: –0.2210 to –0.03669,
p  0.0038
Figure 2B, phospho/total ERK1/2 with 50 M lovastatin/vehicle
Normally distributed Two-way RM ANOVA N  19
per group
Genotype: p  0.0146
(Continued)
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Table 1. Continued
Figure Data structure Statistical test Sample size Statistical data
WT veh vs Fmr1
KO veh
Normally distributed Sidak’s post hoc N  19
per group
CI: –0.02577 to 0.1893,
p  0.1539
Fmr1 KO veh vs
Fmr1 KO lovastatin
Normally distributed Sidak’s post hoc N  19
per group
CI: 0.04797 to 0.2630,
p  0.0048
Figure 2C, phospho/total ERK1/2 with 0.1–0.5 M simvastatin/vehicle
Normally distributed Two-way RM ANOVA N  11
per group
Genotype: p  0.7010,
treatment: p  0.8761
Figure 2D, phospho/total p70S6K with 0.1–0.5 M simvastatin/vehicle
Normally distributed Two-way RM ANOVA N  10
per group
Genotype: p  0.2860,
treatment: p  0.6206
Figure 3B, AGS incidence with 3 mg/kg simvastatin
WT veh vs Fmr1
KO veh




CI: 0.002672 to 0.3437,
p  0.0028
WT simvastatin vs Fmr1
KO simvastatin




CI: 0.002918 to 0.3808,
p  0.0028
Fmr1 KO veh vs
Fmr1 KO
simvastatin




CI: 0.1915 to 5.221,
p  0.9999
Figure 3C, AGS severity distribution scores with 3 mg/kg simvastatin
WT veh vs Fmr1
KO veh
Non-normal distribution Mann–Whitney test N  12
per group
CI: 0.000 to 2.000,
p  0.0028
Fmr1 KO veh vs
Fmr1 KO
simvastatin
Non-normal distribution Mann–Whitney test N  12
per group
CI: –1.000 to 1.000,
p  0.9510
Figure 3D, AGS latency with 3 mg/kg simvastatin
Fmr1 KO veh vs
Fmr1 KO
simvastatin




CI: –11.56 to 43.11,
p  0.2388
Figure 3E, AGS incidence with 50 mg/kg simvastatin
WT veh vs Fmr1
KO veh
Non-normal distribution Two-tailed Fisher’s exact
test
KO veh: n  14
WT veh: n  12
CI: 0.004960 to 0.5143,
p  0.0053
WT simvastatin vs Fmr1
KO simvastatin
Non-normal distribution Two-tailed Fisher’s exact
test
KO simva: n  11
WT simva:n  13
CI: 0.006556 to 0.7356,
p  0.0233
Fmr1 KO veh vs
Fmr1 KO
simvastatin
Non-normal distribution Two-tailed Fisher’s exact
test
KO veh: n  14
KO simva: n  11
CI: 0.2988 to 7.531,
p  0.6968
Figure 3F, AGS severity scores with 50 mg/kg simvastatin
WT veh vs Fmr1
KO veh
Non-normal distribution Mann–Whitney test KO veh: n  14
WT veh: n  12
CI: 0.000 to 3.000,
p  0.0036
Fmr1 KO veh vs
Fmr1 KO
simvastatin
Non-normal distribution Mann–Whitney test KO veh: n  14
KO simva: n  11
CI: –3.000 to 0.000,
p  0.2254
Figure 3G, AGS latency with 50 mg/kg simvastatin
Fmr1 KO veh vs
Fmr1 KO
simvastatin
Normally distributed Unpaired two-tailed
t test
KO veh: n  14
KO simva: n  11
CI: –11.41 to 8.739,
p  0.7794
Figure 3H, AGS incidence with 100 mg/kg lovastatin
WT veh vs Fmr1
KO veh
Non-normal distribution Two-tailed Fisher’s exact
test
KO veh: n  16
WT veh: n  15
CI: 0.01126 to 0.4341,
p  0.0032
WT lovastatin vs Fmr1
KO lovastatin
Non-normal distribution Two-tailed Fisher’s exact
test
KO lova: n  14
WT lova:n  17
CI: 0.06948 to 3.440,
p  0.6358
(Continued)
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 116.52  2.21%, KO 0.3 M  129.15  3.99%, KO
0.5 M 137.01 3.08%; WT veh vs 0.3 M p 0.0002,
WT veh vs 0.5 M p  0.0001, KO veh vs 0.3 M p 
0.0035, KO veh vs 0.5 M p  0.0001; n  9; Fig. 1D).
These results show that unlike lovastatin, simvastatin
does not correct excessive protein synthesis in the
Fmr1-/y hippocampus.
Lovastatin, but not simvastatin, reduces ERK1/2
activation
Our metabolic labeling experiments show that 50 M
lovastatin reduces protein synthesis in the Fmr1-/y hip-
pocampus by 15–20% (Fig. 1B). Conversely, 0.5 M sim-
vastatin causes a 15–20% increase in protein synthesis in
the Fmr1-/y hippocampus (Fig. 1D). Given the opposite
Table 1. Continued




Non-normal distribution Two-tailed Fisher’s exact
test
KO veh: n  16
KO lova: n  14
CI: 1.538 to 42.32,
p  0.0136
Figure 3I, AGS severity distribution scores with 100 mg/kg lovastatin
WT veh vs Fmr1 KO veh Non-normal distribution Mann–Whitney test KO veh: n  16
n  WT
veh: n  15
CI: 0.000 to 3.000,
p  0.0064
Fmr1 KO veh vs
Fmr1 KO lovastatin
Non-normal distribution Mann–Whitney test KO veh: n  16
KO lova: n  14
CI: –3.000 to 0.000,
p  0.0204
Figure 3J, AGS latency with 100 mg/kg lovastatin
Fmr1 KO veh vs
Fmr1 KO
simvastatin
Normally distributed Unpaired two-tailed
t test
KO veh: n  16
KO lova: n  14
CI: 3.595 to 31.07,
p  0.0176
Figure 1. Simvastatin exaggerates excessive protein synthesis in the Fmr1-/y hippocampus. Slices were prepared from WT and
Fmr1-/y hippocampi and incubated in vehicle, lovastatin, or simvastatin at different concentrations. A, Schematic shows time course
for metabolic labeling experiments of hippocampal slices. B, Lovastatin significantly decreases protein synthesis in Fmr1-/y slices to
WT levels (ANOVA genotype p  0.0106; Sidak’s WT veh vs KO veh p  0.0032, KO veh vs KO lova p  0.0368; n  12). C,
Simvastatin raises protein synthesis in both WT and Fmr1-/y slices at 5 M (ANOVA treatment p  0.0001, genotype p  0.0294;
Sidak’s WT veh vs 5 M p  0.0001, KO veh vs 5 M p  0.0001; n  10). D, Simvastatin raises protein synthesis at 0.1–0.5 M,
exaggerating the excessive protein synthesis phenotype (ANOVA treatment p  0.0001, genotype p  0.0068; Sidak’s WT veh vs
0.3 M p  0.0002, WT veh vs 0.5 M p  0.0001, KO veh vs 0.3 M p  0.0035, KO veh vs 0.5 M p  0.0001, WT veh vs
KO veh p  0.0005, WT 0.1 M vs KO 0.1 M p  0.0406, WT 0.3 M vs KO 0.3 M p  0.0115, WT 0.5 M vs KO 0.5 M p
 0.0038; n  9). Representative samples were run on SDS-PAGE gels and transferred to membranes. Example phosphorimages of
35S-labeled proteins and total protein staining of the same membrane are shown. Error bars  SEM. N  littermate pairs.
Figure Contributions: Melania Muscas and Susana R. Louros performed the experiments and analyzed the data.
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effect of lovastatin and simvastatin on protein synthesis,
we wondered whether these compounds acted differently
on the ERK1/2 and mTOR translation control signaling
pathways (Fig. 2A). To confirm the same lovastatin treat-
ment that reduces excess protein synthesis in the Fmr1-/y
also reduces ERK1/2 activation, we incubated slices in
vehicle or 50 M lovastatin and performed quantitative
immunoblotting for p-ERK1/2 (Fig. 2B; Extended Data Fig.
2-1). Our results confirm that 50 M lovastatin signifi-
cantly reduces p-ERK1/2 in Fmr1-/y slices as previously
reported (WT veh  100  4.32%, WT lova  99.28 
4.42%, KO veh  91.83  4.74%, KO lova  76.28 
3.76%; KO veh vs lova p  0.0048; n  19).
Next, to test whether simvastatin had a differential impact on
ERK1/2 signaling at the same concentration that causes a
15–20% increase in protein synthesis, we repeated our immu-
noblotting analysis on slices exposed to vehicle or 0.1–0.5 M
simvastatin. In contrast to lovastatin, our results show that
simvastatin has no significant impact on p-ERK1/2 in eitherWT
or Fmr1-/y slices at any dose tested (WT veh 100 4.51%,
WT 0.1 M  102.87  3.42%, WT 0.3 M  108.45 
4.10%,WT 0.5M 101.01% 2.09%, KO veh 105.63
4.97%, KO 0.1 M  98.94  4.46%, KO 0.3 M 
94.71  4.53%, KO 0.5 M  106.93  3.65%; n  11; Fig.
2C; Extended Data Fig. 2-1). This suggests that simvastatin
neither activates nor inhibits the ERK1/2 pathway under con-
ditions where it increases protein synthesis.
Although our previous study with lovastatin showed no
effect of lovastatin on mTOR activation as assessed by
phosphorylation of p70S6K, we wondered whether simva-
statin had an observable impact on this pathway. To inves-
tigate, we immunoblotted for p-p70S6K in WT and Fmr1-/y
slices treated with 0.1–0.5 Msimvastatin. Our results show
that p70S6K activation is unchanged in slices treated with
0.1–0.5 M simvastatin (WT veh  100  11.14%, WT 0.1
M 112.94 10.25%, WT 0.3M 110.66 9.47%,WT
0.5 M 98.89 4.72%, KO veh 92.87 4.49%, KO 0.1
M 85.37% 11.82%, KO 0.3 M 101.71% 10.37%,
KO 0.5 M  92.53%  10.64%; n  10; Fig. 2D; Extended
Data Fig. 2-1). Together, these experiments show that unlike
lovastatin, simvastatin does not affect the activation of ERK1/2,
nor does it alter the mTORC1-p70S6K pathway.
Lovastatin, but not simvastatin, corrects the AGS
phenotype in the Fmr1-/y mouse
Our work in vitro shows that simvastatin does not cor-
rect the ERK1/2-stimulated excess in protein synthesis in
the Fmr1-/y hippocampus, suggesting that it may not have
the same efficacy as lovastatin in ameliorating pathologic
phenotypes. To directly test this, we performed a side-
by-side analysis of the effect of lovastatin versus simva-
statin on the incidence of AGS in the Fmr1-/y mouse.
Although the AGS phenotype is seen in Fmr1-/y mice bred
on multiple mouse background strains, a more robust
Figure 2. Simvastatin does not reduce ERK1/2 or mTORC1
activation in the Fmr1-/y hippocampus. A, Diagram shows the
potential impact of simvastatin on Ras-ERK1/2 and Rheb-
mTOR-signaling pathways. B, Fmr1-/y slices incubated with 50
M lovastatin show a significant reduction in ERK1/2 phosphor-
ylation (ANOVA genotype p  0.0146; Sidak’s KO veh vs KO
lova p  0.0048; n  19). C, Simvastatin treatment does not
reduce ERK1/2 phosphorylation in Fmr1-/y or WT slices (ANOVA
treatment p  0.8761, genotype p  0.7010; n  11). D, Sim-
vastatin treatment does not reduce phosphorylation of p70S6K
in WT or Fmr1-/y slices (ANOVA treatment p  0.6206, genotype
p  0.2860; n  10). Representative bands were cropped from
original blots as indicated by blank spaces. Original blots are
Figure 2. continued
shown in Extended Data Figure 2-1. Error bars  SEM. N 
littermate pairs.
Figure Contributions: Melania Muscas performed the experi-
ments and analyzed the data.
New Research 8 of 12
May/June 2019, 6(3) e0097-19.2019 eNeuro.org
phenotype is observed in mice bred on the FVB strain or
a C57Bl6/J x FVB hybrid strain (Yan et al., 2004, 2005).
Therefore, we used Fmr1-/y and littermate WT mice bred
on a C57Bl6/J x FVB hybrid strain for our AGS study.
Importantly, lovastatin corrects the AGS phenotype in
Fmr1-/y bred on both C57BL/6J and FVB strains, suggest-
ing the rescue is not dictated by background genetics
(Osterweil et al., 2013).
To test whether simvastatin could similarly correct the
AGS phenotype, we injected Fmr1-/y and littermate WT
mice with 3 mg/kg simvastatin as described in Materials
and Methods. We used the lactone prodrug version of
simvastatin administered to human patients, which is hy-
drolyzed into the active hydroxy acid compound by the
liver (Schachter, 2005). The initial dose of simvastatin was
chosen based on previous work showing 1 mg/kg simva-
statin reduces epileptogenic activity and neurotoxicity in a
kainic acid (KA) rat model of epilepsy (Xie et al., 2011).
Additionally, according to a conversion factor of 0.081 for
mouse to human dosing recommended by the Food and
Drug Administration (FDA), 3 mg/kg simvastatin in mouse
would be equivalent to the 20 mg dose used in humans
(Nair and Jacob, 2016).
Animals were injected with vehicle or simvastatin with
the experimenter blind to genotype and treatment, and
then left in a quiet environment for 1 h before AGS testing.
A 1-h incubation time was chosen based on previous
experiments using lovastatin, and on previous pharmaco-
kinetic studies in mice and rats showing that simvastatin
peaks in blood at 30 min to 1 h after administration (van
de Steeg et al., 2013; Higgins et al., 2014; Xu et al., 2014),
and peaks in brain 1 h after administration (Johnson-
Anuna et al., 2005). To induce AGS, animals were trans-
ferred to a test chamber and exposed to a 2-min digitized
sampling of a personal alarm passed through 50-W
speakers at a level of130 dB. Seizures were recorded at
increasing levels of severity as: 1, wild running (uncon-
trolled and undirected running); 2, clonic seizure (loss of
balance with violent spasms on all limbs); and 3, tonic
seizure (loss of balance with postural rigidity in limbs and
tail; Fig. 3A). Latency between the onset of the AGS
stimulus and seizure was also used as a metric of seizure
severity and measured as the number of seconds be-
tween the start of the alarm to the first appearance of wild
running.
Our results show that vehicle-treated Fmr1-/y mice ex-
hibit a significantly higher incidence of AGS versus WT
littermates (WT veh 8%, KO veh 75%, p  0.0028) and a
significant increase in seizure severity (WT vs KO veh p 
0.0028). However, in contrast to lovastatin, 3 mg/kg sim-
vastatin injection had no significant effect on the inci-
dence of AGS in Fmr1-/y mice (WT veh 8%, WT simva 9%,
KO veh 75%, KO simva 75%; WT vs KO simva p 
0.0028, KO veh vs simva p  1.000; Fig. 3B). Comparison
of AGS scores showed 3 mg/kg simvastatin was similarly
ineffective in reducing seizure severity (KO veh: wild run-
ning 1/12, clonic 5/12, tonic 3/12; KO simva: wild running
3/12, clonic 2/12, tonic 4/12; KO veh vs simva p  0.951;
Fig. 3C). Measurements of the latency to first seizure also
reveal no significant effect of simvastatin treatment (KO
veh  26.33  3.80 s, KO simva  42.11  12.32 s, p 
0.239; Fig. 3D). These results suggest simvastatin is not
effective in correcting AGS in Fmr1-/y mice.
Although 3 mg/kg is consistent with a simvastatin dose
used in previous studies of KA-induced seizure, higher
doses of up to 50 mg/kg have also been investigated with
respect to neurologic phenotypes in rodents (Ramirez
et al., 2011; Ling and Tejada-Simon, 2016). Indeed, intra-
peritoneal injection of 50 mg/kg active simvastatin 24 h
and 30 min before seizure induction protects against
KA-induced seizures in mice (Ramirez et al., 2011), and
increases learning in a mouse model of Alzheimer’s dis-
ease (Li et al., 2006). To ensure that simvastatin is not
effective in correcting the AGS phenotype in Fmr1-/ymice,
we repeated our experiments using a high dose of 50
mg/kg. To remove the potential confound of prodrug
metabolism, we injected active simvastatin hydroxy acid
rather than inactive lactone. In a comparison group, we
tested an equipotent 100 mg/kg dose of active lovastatin
hydroxy acid that was previously shown to correct AGS in
adult Fmr1-/y FVB mice (Osterweil et al., 2013). Separate
groups of Fmr1-/y and WT littermates were injected with
50 mg/kg simvastatin or 100 mg/kg lovastatin (with cor-
responding vehicle) and AGS testing performed as previ-
ously.
Our results show that even at a higher dose, simvastatin
does not reduce AGS incidence in Fmr1-/y mice (WT veh
8%, WT simva 8%, KO veh 64%, KO simva 55%; WT vs
KO veh p  0.0053, WT vs KO simva p  0.0233, KO veh
vs simva p 0.6968; Fig. 3E). AGS severity is similarly not
reduced in simvastatin-treated Fmr1-/y mice as assessed
by seizure score (KO veh: wild running 0/14, clonic 1/14,
tonic 8/14; KO simva: wild running 0/11, clonic 3/11, tonic
3/11; WT vs KO veh p  0.0036, KO veh vs KO simva p
 0.2254; Fig. 3F) or latency to seizure onset (KO veh 
27  2.95 s, KO simva  25.67  3.61 s, p  0.779; Fig.
3G). In contrast, Fmr1-/y mice injected with 100 mg/kg
lovastatin showed a significant reduction in AGS versus
vehicle-treated mice (WT veh 13%, WT lova 12%, KO veh
69%, KO lova 21%; WT vs KO veh p 0.0032, KO veh vs
lova p  0.0136, WT veh vs KO lova p  0.6513; Fig. 3H).
Additionally, AGS scoring reveals a decrease in the se-
verity of seizures in lovastatin-treated Fmr1-/y mice (KO
veh: wild running 0/16, clonic 5/16, tonic 6/16; KO lova:
wild running 0/14, clonic 1/14, tonic 2/14; WT vs KO veh
p 0.0064, KO veh vs KO lova p 0.0204; Fig. 3I), and
an increase in the latency to the first seizure (KO veh  28
 3 s, KO lova  45.33  4.84 s, KO veh vs lova p 
0.0176; Fig. 3J). Together, these results show that lova-
statin reduces the incidence and severity of AGS in the
Fmr1-/y, whereas simvastatin has no effect.
Discussion
The promising results using lovastatin in FX have led to
the suggestion that simvastatin may be similarly effective.
In this study, we investigated two core phenotypes in the
Fmr1-/y mouse model to test the prediction that simvasta-
tin can be used in place of lovastatin. Our results show
that simvastatin not only fails to correct excessive protein
synthesis in the Fmr1-/y hippocampus, it worsens this
New Research 9 of 12
May/June 2019, 6(3) e0097-19.2019 eNeuro.org
Figure 3. Simvastatin does not correct AGS in the Fmr1-/y mouse. Fmr1-/y and littermate WT mice were injected intraperitoneally with
vehicle, simvastatin, or lovastatin and tested for AGS. A, Schematic shows the experimental timeline and scoring system for AGS
testing. B, Injection of 3 mg/kg simvastatin does not reduce the incidence of AGS in Fmr1-/y mice (Fisher’s exact test WT vs KO veh
p  0.0028, WT vs KO simva p  0.0028, KO veh vs simva p  0.999). C, Comparison of AGS scores also shows no reduction of
seizure severity with 3 mg/kg simvastatin (Mann–Whitney WT vs KO veh p  0.0028, KO veh vs KO simva p  0.9510). D, 3 mg/kg
simvastatin does not increase latency to first seizure in Fmr1-/y mice (unpaired t test p  0.239). E, 50 mg/kg active simvastatin does
not reduce AGS incidence in Fmr1-/y mice (Fisher’s exact test WT vs KO veh p  0.0053, WT vs KO simva p  0.0233, KO veh vs
simva p  0.6968). F, AGS severity scores are not significantly reduced with 50 mg/kg simvastatin (Mann–Whitney WT vs KO veh p
 0.0036, KO veh vs KO simva p  0.2254). G, Latency to first seizure is not significantly different between vehicle and 50 mg/kg
simvastatin-treated Fmr1-/y mice (unpaired t test p  0.779). H, Injection of 100 mg/kg lovastatin significantly reduces the incidence
of AGS in Fmr1-/y mice (Fisher’s exact test WT vs KO veh p  0.0032, WT vs KO lova p  0.6358, KO veh vs lova p  0.0136).
I, Lovastatin reduces severity scores of AGS in Fmr1-/y mice versus vehicle (Mann–Whitney WT vs KO veh p  0.0064, KO veh vs
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phenotype (Fig. 1). We do not see a reduction of ERK1/2
activation at the concentrations of simvastatin tested (Fig.
2). Moreover, simvastatin does not reduce the incidence
or severity of AGS in the Fmr1-/y mouse even at a high
dose of 50 mg/kg (Fig. 3). These results suggest that
simvastatin should not be assumed to be an effective
replacement for lovastatin with respect to correction of
Fmr1-/y pathology.
Although we propose the beneficial effect of lovastatin
stems from the inhibition of ERK1/2-driven protein syn-
thesis, it is important to note that statins are capable of
affecting several biochemical pathways. Beyond the ca-
nonical impact on cholesterol biosynthesis, statins also
decrease isoprenoid intermediates including farnesyl and
geranylgeranyl pyrophosphates that regulate membrane
association for many proteins including the small GT-
Pases Ras, Rho, and Rac (Schafer et al., 1989; Liao and
Laufs, 2005; Nürenberg and Volmer, 2012; Ling and
Tejada-Simon, 2016). The increase in protein synthesis
seen with simvastatin could be linked to altered post-
translational modification of these or other proteins. In-
deed, although we see no change in mTORC1-p70S6K
signaling, other studies have shown an activation of the
PI3 kinase pathway that could be contributing to this
effect (Mans et al., 2010). However, our comparison of
lovastatin and simvastatin shows that there is a clear
difference in the correction of pathology in the Fmr1-/y
model, suggesting that the impact on ERK1/2 is an im-
portant factor in terms of pharmacological treatment for
FX.
There are many reasons why statins would be an at-
tractive option for treating neurodevelopmental disorders
such as FX. They are prescribed worldwide for the treat-
ment of hypercholesterolemia and coronary heart disease
(Istvan, 2003), and safely used for long-term treatment in
children and adults (Ling and Tejada-Simon, 2016). How-
ever, our study suggests that care should be taken when
considering which statin should be trialed for the treat-
ment of FX and other disorders of excess Ras. Although
the effect of different statins on cholesterol synthesis has
been well documented, the differential impact on Ras-
ERK1/2 signaling is not well established. We show here
that, contrary to lovastatin, simvastatin fails to inhibit the
Ras-ERK1/2 pathway in the Fmr1-/y hippocampus, exac-
erbates the already elevated protein synthesis phenotype,
and does not correct the AGS phenotype. These results
are significant for considering future studies with lova-
statin or simvastatin in FX or other disorders of excess
Ras. Indeed, clinical trials using simvastatin for the treat-
ment of NF1 have shown little promise, while trials with
lovastatin show an improvement in cognitive deficits (van
der Vaart et al., 2013; Bearden et al., 2016; Payne et al.,
2016). Although further studies testing a broader dose
range of simvastatin on additional Fmr1-/y brain pheno-
types will ultimately determine the feasibility of this strat-
egy for FX, our study suggests caution should be used
when assuming simvastatin is a suitable substitute for
lovastatin.
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